Arquitos Capital Management – LQDA
Bull thesis on Liquidia Corporation from Arquitos Capital Management
Liquidia Corporation
Pitch Summary: Liquidia Corporation has shown significant progress with its lead product, Yutrepia, which has received FDA approval for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company has achieved strong revenue growth and positive cash flow, with a promising pipeline including L606, a potential superior formulation. Despite insider sales […]
